Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.

ABSTRACT:

Background

Postmarketing evaluations have linked myocarditis to SARS-CoV-2 mRNA vaccines. We sought to estimate the incidence of myocarditis after mRNA vaccination against SARS-CoV-2, and to compare the incidence with expected rates based on historical background rates in British Columbia.

Methods

We conducted an observational study using population health administrative data from the BC COVID-19 Cohort from Dec. 15, 2020, to Mar. 10, 2022. The primary exposure was any dose of an mRNA vaccine against SARS-CoV-2. The primary outcome was incidence of hospital admission or emergency department visit for myocarditis or myopericarditis within 7 and 21 days postvaccination, calculated as myocarditis rates per 100 000 mRNA vaccine doses, expected rates of myocarditis cases and obse

SUBMITTER: Naveed Z 

PROVIDER: S-EPMC9828950 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature